ArticleOncotarget2017
Identification of a three miRNA signature as a novel potential prognostic biomarker in patients with bladder cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- From Osteogenesis to Diagnosis: The Role of microRNAs as Biomarkers for Osteoporosis.International journal of molecular sciences · 2026Review
- MicroRNA signatures of cardiorespiratory fitness (VO2peak) in older adults: Insights from the study of muscle, mobility, and aging.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Article
- miR-486 is involved in the pathogenesis of acute myeloid leukemia by regulating JAK-STAT signaling.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Small Nucleolar RNAs (snoRNAs)-Based Risk Score Classifier Predicts Overall Survival in Bladder Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- TLR5: A prognostic and monitoring indicator for triple-negative breast cancer.Cell death & disease · 2019Article
- TLR5 is a new reporter for triple-negative breast cancer indicated by radioimmunoimaging and fluorescent staining.Journal of cellular and molecular medicine · 2019Article
- MicroRNAs: Key Players in Bladder Cancer.Molecular diagnosis & therapy · 2019Review
- Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles.International journal of molecular sciences · 2019Review
- An eight-mRNA signature predicts the prognosis of patients with bladder urothelial carcinoma.PeerJ · 2019Article
- A co-expression network for differentially expressed genes in bladder cancer and a risk score model for predicting survival.Hereditas · 2019Article
- Enhanced plasma miR-26a-5p promotes the progression of bladder cancer via targeting PTEN.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is not a good biomaker that is closely related to survival time for bladder cancer(BLCA), The aim of the study is to identify a miRNA signature that could predict prognosis in BLCA patients according to the data from The Cancer Genome Atlas (TCGA). a total of 377 BLCA patients were finally enrolled in the study. The three miRNA signature was identified by Multivariate Cox proportional hazards analyses that common clinical variables were controled. The three microRNA signature showed greater predicting prognosis capacity for predicting 5-year survival in BLCA with an AUC of 0.664, 0.681 and 0.668 in Train set, Test set and Total set respectively. Furthermore, there was a significant difference between high score and low score in Total set(P=3e-05), Test set(P=0.00435) and Train set(P=0.00143), respectively. Therefore, these results provided a new prospect for prognostic biomarker of BLCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.